Accessibility Menu
 
Aldeyra Therapeutics logo

Aldeyra Therapeutics

(NASDAQ) ALDX

Current Price$1.85
Market Cap$111.34M
Since IPO (2014)-74%
5 Year-83%
1 Year-72%
1 Month-63%

Aldeyra Therapeutics Financials at a Glance

Market Cap

$111.34M

Revenue (TTM)

$0.00

Net Income (TTM)

$33.85M

EPS (TTM)

$-0.56

P/E Ratio

-3.28

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Price

$1.85

Volume

133,245

Open

$1.98

Previous Close

$1.85

Daily Range

$1.75 - $1.99

52-Week Range

$1.07 - $6.73

ALDX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aldeyra Therapeutics

Industry

Biotechnology

Employees

8

CEO

Todd C. Brady, MD, PhD

Headquarters

Lexington, MA 02421, US

ALDX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-59%

Return on Capital

-0%

Return on Assets

-0%

Earnings Yield

-30.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$111.34M

Shares Outstanding

60.18M

Volume

133.25K

Short Interest

0.00%

Avg. Volume

2.70M

Financials (TTM)

Gross Profit

$251.99K

Operating Income

$35.27M

EBITDA

$31.69M

Operating Cash Flow

$33.35T

Capital Expenditure

$0.00

Free Cash Flow

$33.35T

Cash & ST Invst.

$70.04T

Total Debt

$15.53T

Aldeyra Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$65.11K

-1.2%

Gross Margin

0.00%

N/A

Market Cap

$111.34M

N/A

Market Cap/Employee

$12.37M

N/A

Employees

9

N/A

Net Income

$6.46M

+59.1%

EBITDA

$1.09T

+7106395.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$54.51T

+63496911.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$15.53T

+5125417470.1%

Return on Assets

-0.00%

N/A

Return on Invested Capital

-0.00%

N/A

Free Cash Flow

$28.20T

+234241228.0%

Operating Cash Flow

$28.20T

+234241228.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNLXGenelux Corporation
$2.65+9.50%
MREOMereo BioPharma Group plc
$0.35+4.11%
SLNSilence Therapeutics plc
$5.47+5.19%
CADLCandel Therapeutics, Inc.
$4.99+3.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$10.31-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.31-0.04%
TERNTerns Pharmaceuticals
$52.86+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$44.39+0.02%

Questions About ALDX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.